CALAB, INC. Competitors

VistaGen Therapeutics (NASDAQ: VTGN) is a clinical-stage biopharmaceutical company developing new generation medicines for multiple CNS diseases and disorders with high unmet need. Our CNS pipeline includes three drug candidates (AV-101, PH10, and PH94B) with potential for at-home use, rapid-onset therapeutic benefits and exceptional safety. Each CNS drug candidate in our pipeline is either currently in or has completed Phase 2 clinical development. AV-101, an oral NMDA receptor glycine site antagonist (a full antagonist), is in Phase 2 development in the U.S. for major depressive disorder (MDD) and in a first-step target engagement study in healthy volunteer U.S. military Veterans for suicidal ideation. The FDA has granted Fast Track designation for development of AV-101, both as a potential adjunctive treatment for MDD and as a non-opioid treatment for neuropathic pain. PH10 is a potential first-in-class neuroactive nasal spray with rapid-onset antidepressant effects observed at microgram doses and without systemic exposure. PH10 is in Phase 2 development for MDD. PH94B is a potential first-in-class neuroactive nasal spray with rapid-onset effects observed at microgram doses and without systemic exposure. Phase 2 and pilot Phase 3 development of PH94B for Social Anxiety Disorder (SAD) has been completed successfully, and PH94B is now being prepared for pivotal Phase 3 development as an on-demand PRN treatment for SAD. VistaStem Therapeutics is VistaGen's wholly owned subsidiary focused on applying human pluripotent stem cell technology, internally and with collaborators, to discover, rescue, develop and commercialize proprietary new chemical entities (NCEs), including small molecule NCEs with regenerative potential, for CNS and other diseases, and cellular therapies involving stem cell-derived blood, cartilage, heart and liver cells.

Med Tech Solutions (MTS) puts the unique needs of each healthcare organization at the center of our work across the full IT journey. Our healthcare-exclusive services employ dedicated ITCare Teams to ensure technology systems support essential clinical workflows and strategic business plans. Provider organizations and networks can count on a secure, reliable IT infrastructure, optimized clinical and business applications, revenue cycle management services, and full end-user support so they can focus on patient care. MTS was founded in 2006 in Valencia, California, and serves thousands of healthcare organizations nationwide. The company is the top-ranked IT services firm for healthcare organizations on the elite Channel Futures MSP 501 list and has been recognized as a 2023 CRN Pioneer 250 Honoree. MTS has achieved HITRUST Risk-based certification for its cloud platform, demonstrating a proactive approach to cybersecurity, data protection, and risk management. Learn more at www.medtechsolutions.com.

Elite Diagnostics is a Charlotte, North Carolina based company that provides end-to-end toxicology laboratory consulting, solutions, and management to a diverse range of healthcare clients. Our success has been powered by a dynamic group of experienced scientists, technicians, and business professionals pursuing the most cost-efficient, quality-driven toxicology testing methodologies in the industry. Our technical approach is driven by a qualified team with more than 30 years of experience in toxicology testing and laboratory management. Elite’s management led the scientific and operational teams for the third biggest toxicology lab in the nation with annual revenue in excess of $100 million. It was the first toxicology lab with Platinum Accreditation by A2LA and ISO:15189;2012 accreditation. For questions about Elite's services - or to find out more about how we can help, please visit our website at www.elitediagnostics.com/.